Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality
Nicolas Richard, Marie Hudson, Mianbo Wang, Genevieve Gyger, Susanna Proudman, Wendy Stevens, Mandana Nikpour, J Pope, M Larche, N Khalidi, A Masetto, E Sutton, D Robinson, TS Rodriguez-Reyna, D Smith, C Thorne, PR Fortin, M Fritzler, L Croyle, J de Jager Show all
RHEUMATOLOGY | OXFORD UNIV PRESS | Published : 2019
OBJECTIVES: To examine the incidence, predictors and outcomes associated with severe gastrointestinal (GI) disease in a large inception SSc cohort. METHODS: SSc subjects with 2-fold increase in the risk of death (hazard ratio 2.27, 95% CI 1.27, 4.09) and worse health-related quality of life [Short Form Health Survey physical (β = -2.37, P = 0.02) and mental (β = -2.86, P = 0.01) component summary scores]. CONCLUSION: Severe GI disease is common in early SSc and is associated with significant morbidity and increased mortality. More research is needed to understand, prevent and mitigate severe GI disease in SSc.
Related Projects (1)
Awarded by Canadian Institutes of Health Research (CIHR)
Awarded by National Health and Medical Research Council of Australia Career Development Fellowship
The Canadian Scleroderma Research Group (CSRG) is funded by the Canadian Institutes of Health Research (CIHR) (grant #FRN 83518), the Scleroderma Society of Canada and its provincial Chapters, Scleroderma Society of Ontario, Scleroderma Society of Saskatchewan, Sclerodermie Quebec, Cure Scleroderma Foundation, INOVA Diagnostics Inc. (San Diego, CA, USA), Dr Fooke Laboratorien GmbH (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen GmbH (Neuried, Germany), Fonds de la recherche du Quebec - Sante (FRQS), the Canadian Arthritis Network (CAN) and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, QC. The CSRG has also received educational grants from Pfizer and Actelion pharmaceuticals. M.H. is funded by the Fonds de la recherche du Quebec - Sante (FRQS). The Australian Scleroderma Interest Group (ASIG) is supported by Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Actelion Australia, MOVE, The Australian Rheumatology Association, The Scleroderma Clinical Trials Consortium, St Vincent's Hospital Research Endowment Fund, Bayer, CSL Biotherapies, GlaxoSmithKline Australia, Roche and Pfizer. N.R. is funded by the Hopital Maisonneuve Rosemont Department of Medicine Foundation Fund. M.H. is funded by the Fonds de la recherche du Quebec - Sante (FRQS). M.N. holds a National Health and Medical Research Council of Australia Career Development Fellowship (APP 1126370).